Clinacin 150 mg Tablets

Country: United Kingdom

Language: English

Source: VMD (Veterinary Medicines Directorate)

Active ingredient:

Clindamycin

Available from:

Chanelle Animal Health Ltd

ATC code:

QJ01FF01

INN (International Name):

Clindamycin

Pharmaceutical form:

Tablet

Prescription type:

POM-V - Prescription Only Medicine – Veterinarian

Therapeutic group:

Dogs

Therapeutic area:

Antimicrobial

Authorization status:

Authorized

Authorization date:

2002-03-12

Summary of Product characteristics

Revised: March 2019
AN: 01178/2018
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Clinacin 150mg Tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCE: Clindamycin, 150mg (as Clindamycin Hydrochloride)
EXCIPIENT(S): for a full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Tablets.
An oblong white tablet with a breakline on one side.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Clinacin 150 mg Tablets are indicated in dogs for the treatment of
infected
wounds, abscesses, superficial pyoderma and oral cavity/dental
infections
caused by or associated with clindamycin-sensitive staphylococci,
streptococci, bacteroidaceae, _Fusobacterium necrophorum_,
_Clostridium _
_perfringens_ and osteomyelitis caused by _Staphylococcus aureus_.
Clinacin
150 mg Tablets can also be used to help provide antimicrobial cover
during
dental procedures.
4.3
CONTRAINDICATIONS
Do not administer to animals with hypersensitivity to clindamycin and
lincomycin preparations. Do not administer to rabbits, guinea pigs,
chinchillas, hamsters, horses or ruminants.
Revised: March 2019
AN: 01178/2018
Page 2 of 5
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Before
use
of
Clinacin
150
mg
tablets,
the
identification
of
causative
pathogenic micro-organisms should be carried out and their
susceptibility to
clindamycin should be established.
Clindamycin and lincomycin show parallel-resistance. There is a
partial
cross-resistance to erythromycin and other macrolide-antibiotics
4.5
SPECIAL PRECAUTIONS FOR USE
I.
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
During prolonged therapy of one month or greater, periodic liver and
kidney
function tests and blood counts should be performed. Patients with
severe
renal
and/or
very
severe
hepatic
disturbances
accompanied
by
severe
metabolic aberrations should be dosed with caution and should be
monitored
by serum examination during high dose clindamycin therapy.
II.
SPECIAL PRECAUTIONS FOR THE PERS